MedTrace Logo

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

NCT07669779 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2026-07-14

No results posted yet for this study

Summary

This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.

Conditions

  • Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

AK146D1 for injection

AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate.

DRUG

AK112 Injection

AK112 is a PD-1/VEGF bispecific antibody.

DRUG

Platinum chemotherapy

Carboplatin or cisplatin will be administered.

DRUG

Osimertinib

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-10
Primary Completion
2027-08-30
Completion
2029-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07669779 on ClinicalTrials.gov